MRM — MEDIROM Healthcare Technologies Share News
0.000.00%
- $2.75m
- $16.74m
- ¥8bn
Brief: Medirom Decides To Double Installation Of Authentication Device “Orb” To 200 Stores
Brief: Medirom Healthcare Technologies Inc Files For Mixed Shelf Of Up To $50 Million - SEC Filing
U.S. STOCKS ON THE MOVE-Centrus Energy, Tempus AI, Hagerty
Medirom jumps as co partners with ChatGPT creator Sam Altman's World
Brief: MEDIROM Mother Labs Executive Makes Additional Investment in Mother Labs’ Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of March 13, 2025, Approximately US$60 Million)
Brief: Medirom Healthcare Technology's Unit, Medirom Mother Labs, Raises An Aggregate Total Of JPY260.3 Million In Its Series A Financing Round
Brief: Medirom Healthcare Technologies Inc. Announces Closing Of Public Offering
Brief: Medirom Healthcare Technologies Inc Prices Public Offering Of 2.86 Million Shares At $1.75 Each
Brief: Medirom Healthcare Technologies Joins Medirom Mother Labs' Series A Financing Round
Brief: Capital And Business Alliance Formed Between Medirom Mother Labs And NFES Technologies
Brief: Medirom Healthcare Technologies Says Capital And Business Alliance Formed Between Medirom Mother Labs And NFES Technologies
Brief: MEDIROM Healthcare Technologies Announces Business Transfer From Y’s
Brief: Medirom Healthcare Technologies Inks Share Transfer Agreement To Acquire 70% Of Shares Of Japan Gene Medicine From An Individual Shareholder
Brief: Medirom Healthcare Technologies Entered Into A MOU For Purpose Of Acquiring All Shares Of Stock Of Japan Gene Medicine Corporation
Brief: Medirom Healthcare Technologies Inc Number Of Salons Was 314 In December 2023, Up From 312 In The Year-Ago Period
Brief: Medirom Healthcare Technologies Announces May 2023 Key Performance Indicators (KPIS)
Brief: Medirom Healthcare Technologies Successfully Appeals Nasdaq Delisting Notice
Brief: Medirom Healthcare Technologies Announces Preliminary, Unaudited Financial Results For 2022
Brief: On December 28, Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq